Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Uterine fibroid treatment drugs industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Drug class trends
2.1.4 Type trends
2.1.5 Distribution channel trends
Chapter 3 Uterine Fibroid Treatment Drugs Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of uterine fibroid
3.2.1.2 Development of new drugs for women with uterine fibroids
3.2.1.3 Growing awareness about uterine fibroids
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with uterine fibroid treatment drugs
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By type
3.3.3 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Uterine Fibroid Treatment Drugs Market Estimates and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 Progestin-releasing intrauterine device (IUD) & contraceptives
5.3 Gonadotropin-releasing hormone (GnRH) antagonists
5.4 Gonadotropin-releasing hormone (GnRH) agonists
5.5 Non-hormonal medications
5.6 Other drug classes
Chapter 6 Uterine Fibroid Treatment Drugs Market Estimates and Forecast, By Type (USD Million)
6.1 Key trends, by type
6.2 Submucosal fibroids
6.3 Intramural fibroids
6.4 Subserosal fibroids
6.5 Pedunculated fibroids
Chapter 7 Uterine Fibroid Treatment Drugs Market Estimates and Forecast, By Distribution Channel (USD Million)
7.1 Key trends, by distribution channel
7.2 Retail pharmacies
7.3 Hospital pharmacies
7.4 Other distribution channels
Chapter 8 Uterine Fibroid Treatment Drugs Market Estimates and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Switzerland
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Pfizer, Inc.
9.2 Abbvie, Inc.
9.3 AstraZeneca plc
9.4 Bayer AG
9.5 Myovant Sciences Gmbh
9.6 Ferring B.V.
9.7 Amring Pharmaceuticals Inc.
9.8 Theramex
9.9 Watson Pharma, Inc.
